Market News
Stay updated with the latest market trends, earnings, and economic indicators.
A new-age thirst for beverages is emerging as a key force in India's consumer goods market
Beverage industry in India: Indian companies are seeing strong growth in drinks like coffee, ready-to-drink options, and protein beverages. Younger consumers are driving this trend, seeking convenience and health. Companies are expanding their offerings to meet this demand. This shift presents significant opportunities for future expansion in the Indian beverage market.
After Zudio boom, Trent still has a long runway for growth: Noel Tata
Trent Chairman Noel Tata sees the retail firm in its early growth phase. He is confident of achieving ambitious revenue targets. The company plans to build distinct brands and take them to international markets. Trent's strategy focuses on a portfolio of brands catering to diverse customer needs. This approach will guide future expansion.
Reliance operationalises clean energy giga complex; elevates national exchequer contribution to Rs 2,16,472 crore in FY26
Reliance Industries has launched its clean energy operations. The company commissioned solar module manufacturing and began advanced work on a battery storage giga-factory. Reliance also significantly increased its contributions to the national exchequer. Jio Platforms accelerated its research and development, filing numerous new patents. The company is focused on enabling India's energy and digital future.
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector
Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the industry.
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving profitability. Future growth is anticipated from capacity expansions and new product lines. The company's contract development and manufacturing business is also expanding. Investors are watching Gland Pharma's growth prospects.
Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?
Zydus Lifesciences shares climbed to a new 52-week high. The company reported a 9% rise in net profit and over 16% revenue growth for the January-March quarter. A Rs 1,100 crore share buyback was announced. Analysts from Nomura, Nuvama, Motilal Oswal, and JM Financial shared their views on the company's performance and future prospects.
Zydus Lifesciences to pursue acquisitions in specialty, rare diseases
Zydus Lifesciences is set to acquire US firm Assertio Holdings for $166.40 million. This move aims to build a strong specialty oncology business in the US. The company reported robust financial growth for the fourth quarter of 2025-26. Zydus also announced a share buyback and a dividend. Future growth is expected from its specialty portfolio.
Open to 4-5 acquisitions, but at sensible valuations: Ameera Shah, promoter and executive chairperson, Metropolis Healthcare
Metropolis Healthcare is set for its next growth phase. The diagnostic chain will focus on genomics and specialty diagnostics. Strategic acquisitions will also play a key role. The company aims to expand services beyond pathology. This strategy will drive future growth and strengthen its market position.
Alembic Pharma gets USFDA tentative nod for generic prostate cancer drug
Alembic Pharmaceuticals has secured tentative approval from the USFDA for its generic version of Darolutamide tablets, targeting prostate cancer treatment. The approval is for the 300 mg strength. The drug is a generic version of Nubeqa Tablets. The robust market potential for these tablets suggests promising future growth for Alembic.
Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked target
Cipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despite a weak Q4 performance. The stock hit an intraday high of Rs 1,432.10 as investors focused on future growth prospects over near-term earnings pressure.
Margin revival, Semaglutide launch to drive Dr Reddy’s growth momentum in FY27
Dr Reddy's Laboratories anticipates a gradual recovery this fiscal year. The company faced a profit drop last year due to US business pressures. However, operations in India, Europe, and emerging markets show healthy growth. New launches like Semaglutide and Abatacept are expected to drive future expansion. Margins are set to improve with better product mix and cost controls.
From oncology to obesity, Pfizer bets big on India for its next growth wave
Pfizer is focusing on India for future growth. The company plans to launch new medicines quickly and at affordable prices. India is seen as a crucial market for new treatments in cancer, obesity, and vaccines. Pfizer is also working on local clinical studies for future drug launches.